Trial Profile
A Phase III, Double-Blind, Non-inferiority Study of Favipiravir versus Oseltamivir Phosphate in Patients with Influenza Virus Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Toyama Chemical
- 27 May 2016 New trial record